INTRODUCTION {#S1}
============

Ovarian cancer is a highly diverse disease with a high rate of overall mortality ([@R75]). High-grade serous ovarian cancer (HGSC) is the most common and aggressive type of epithelial ovarian cancer, exhibiting high levels of tumor heterogeneity and variable clinical outcomes ([@R29]). Molecular abnormalities in HGSC include *TP53* mutations in virtually all tumors, somatic or germline *BRCA* mutations in \~25% ([@R6]; [@R7]; [@R27]; [@R73]), and extensive copy number changes and *CCNE1* amplification ([@R7]; [@R64]; [@R82]). The heterogeneity and apparent adaptability of the HGSC genome under selective pressure by chemotherapy likely explains the high rates of drug resistance ([@R5]; [@R35]; [@R81]). Despite prior efforts such as The Cancer Genome Atlas (TCGA) ([@R7]; [@R87]; [@R38]; [@R64]) and other analyses that were predominantly focused on samples from patients with HGSC who had upfront debulking surgery, an understanding of the molecular and cellular heterogeneity of HGSC based on highly clinically annotated samples is lacking.

The extent of residual disease following upfront cytoreductive surgery for HGSCisone ofthe strongest prognosticfactors for progression-free and overall survival ([@R16]; [@R88]). Neoadjuvant chemotherapy (NACT) followed by interval cytoreductive surgery has been offered as an alternative approach, especially where full cytoreductive surgery is not feasible ([@R3]). While primary complete gross resection (R0) is related to better clinical outcomes, it is unknown whether that benefit is the result of aggressive surgical efforts or biological differences inherent in disease that is amendable to complete resection. To address this question, a consistent approach to upfront management is needed. We implemented a quality improvement program using a validated laparoscopic scoring algorithm; this approach enables the collection of well-annotated samples prior to definitive surgery or chemotherapy ([@R58]; [@R21]). In the current study, to assess molecular and cellular differences between clinically defined groups, we carried out a highly detailed analysis of primary tumors and multiple metastatic sites from patients with HGSC who had R0 resection versus those who were triaged to NACT, consisting of intravenous paclitaxel and carboplatin, and had either excellent or poor response. HGSC tissue samples were subjected to high-pass whole-genome sequencing (WGS), targeted deep sequencing ([@R8]), RNA sequencing (RNA-seq), reverse-phase protein array (RPPA), mass spectrometry (MS)-based proteomics and phosphoproteomics, immune profiling, and integrated data analysis.

RESULTS {#S2}
=======

Patient Population {#S3}
------------------

The study design and the demographic and clinical characteristics for the 30 patients with HGSC are described in [Figure 1](#F1){ref-type="fig"} and [Table S1](#SD2){ref-type="supplementary-material"}. The patient groups evaluated were as follows: R0, no visible residual disease after primary surgery (n = 10); NACT-PR, poor response to NACT (n = 10); and NACT-ER, excellent response to NACT (n = 10).

Somatic Mutation Analysis by WGS {#S4}
--------------------------------

We performed WGS analyses with average somatic coverage of 118X (from one primary and two metastatic tissue samples per patient) and germline coverage of 38X (from patient-matched blood samples). For 75 samples with high-purity tumors (≥75% proportion of cancer cells), an average of 13,653 somatic variants from each sample were identified for the entire cohort. Within the coding regions, on average, 66 missense mutations, 4 nonsense mutations, 31 silent mutations, and 15 small InDels were found per sample. The mutation load was not statistically significantly different among the three groups or between the R0 and the combined NACT-ER/PR groups ([Figure S1A](#SD1){ref-type="supplementary-material"}). Based on a known list of driver genes ([@R4]; [@R7]), a driver mutation landscape was plotted ([Figures 2A](#F2){ref-type="fig"} and [S1B](#SD1){ref-type="supplementary-material"}). Overall, 14 ovarian-cancer-associated genes were found mutated in our patient cohort. As expected, the most frequently mutated gene was *TP53* in both primary and metastatic sites in all three groups. However, nonsense mutations in *TP53* were exclusively identified in the NACT groups, while in R0, most *TP53* mutations were missense mutations. Specifically, among all NACT-ER and NACT-PR cases including primary and metastatic sites, 36% and 15.4% carried nonsense mutations in *TP53*, respectively. Among all R0 cases, 62.5% carried *TP53* missense mutations. Also, nonsense mutations in *CSMD3* and *PIK3CA* were exclusively identified in both primary and metastatic sites in the NACT-PR group. When comparing primary and metastatic sites, the majority of the mutations (82%) in the driver genes were consistent. Next, utilizing all somatic mutations in our cohort, we identified two distinct mutation signatures that are highly correlated with Signature 3 and Signature 5 reported by the Catalogue of Somatic Mutations in Cancer (COSMIC) database ([Figure S1C](#SD1){ref-type="supplementary-material"}). Interestingly, both signatures were enriched in all three patient groups ([Figure S1D](#SD1){ref-type="supplementary-material"}). Signature 3 has been found in breast, ovarian, and pancreatic cancers and is strongly associated with germline and somatic *BRCA1* and *2* mutations in ovarian cancers ([@R65]).

To address intra-patient tumor heterogeneity, we first compared the repertoire of somatic mutations identified in primary and metastatic sites from each patient ([Figures S2A](#SD1){ref-type="supplementary-material"}--[S2C](#SD1){ref-type="supplementary-material"}). Substantial heterogeneity was observed, with median percentages of trunk mutations of 23% in the R0 group, 31% in the NACT-ER group, and 29% in the NACT-PR group. We next performed clonal analysis for all the somatic mutations identified in WGS to determine the extent to which genotypically distinct clonal cell populations (referred to herein as "clones") exist in the HGSC subsets ([Figure S2D](#SD1){ref-type="supplementary-material"}). The number of mutation clusters and the cellular prevalence of clones were estimated for each patient (both primary and metastatic sites). The number of clones, the size of major clones, and the cellular prevalence of major clones were compared among the groups. We observed large variations within each patient group, and no statistically significant differences were found between any of the groups. Next, we constructed phylogenetic trees of tumors for each group ([Figures S2E](#SD1){ref-type="supplementary-material"}--[S2G](#SD1){ref-type="supplementary-material"}). We observed three possible scenarios. One implies that a dominant clone seeds all metastases, where the primary tumor and all metastases share the same founding driver mutations. Another scenario implies that a subclone evolves and gives rise to all metastases. The third scenario implies that a new subclone with additional driver mutations evolves and seeds some metastases.

Copy Number and Structure Variations {#S5}
------------------------------------

Next, we examined copy number variations (CNVs) and structure variations (SVs) across the entire genome, and no significant differences in the number of CNV breakpoints were found among the three groups ([Figures S3A](#SD1){ref-type="supplementary-material"} and [S3B](#SD1){ref-type="supplementary-material"}). We also examined the frequency of CNVs in primary and metastatic sites in ovarian cancer genes for the three groups ([Figure 2B](#F2){ref-type="fig"}) and compared the enriched mutations of all genes and ovarian-cancer-related genes in the R0 compared to the NACT-ER/PR group ([Figure 2C](#F2){ref-type="fig"}) and the NACT-ER compared to the NACT-PR group ([Figure S3C](#SD1){ref-type="supplementary-material"}). The most frequent CNVs in the R0 group were copy number gain/loss of *CSMD3* (67%) and copy number loss of *NF1* (54%), *CDK12* (50%), and *CCND2* (46%) in both primary and metastatic sites. In comparison, the most frequent CNVs in the NACT-ER group were copy number gains/losses of *NOTCH3* (48%) and *CCND2* (44%) in both primary and metastatic sites, while the most frequent in the NACT-PR group were copy gains of *CCNE1* (46%) and *PIK3CA* (42%) in both primary and metastatic sites. Interestingly, copy number losses of *NF1* were significantly lower in the NACT-ER/PR group (18%, p = 0.002), especially in the NACT-PR group (8%, p = 0.0004), than in the R0 group (54%). In contrast, CNVs of *AKT2* were more frequently observed in the NACT (NACT-ER, 48%; NACT-PR, 35%) than in the R0 (8%, p = 0.004) groups. We further performed copy number signature analysis and compared the similarity between reported copy number signatures in HGSC ([@R51]) and the seven signatures identified in our cohort ([Figures S3D](#SD1){ref-type="supplementary-material"}--[S3H](#SD1){ref-type="supplementary-material"}). Based on the signature exposure in each sample, no significant differences were observed among the R0, NACT-ER, and NACT-PR groups. Next, we examined differences in SVs and SV signatures reported in ovarian cancers. Based on the scores of five SV signatures in each patient, no significant patterns of clusters were observed among the three groups. We identified lists of SVs in ovarian-cancer-associated genes for the three groups, and no recurrent SVs across patients within each group were observed.

Confirmation of WGS Findings by Deep Targeted Sequencing {#S6}
--------------------------------------------------------

While high-pass WGS is known to be quite reliable for identifying mutations, we also utilized high-depth targeted sequencing using the T200.2 panel to test for the consistency of sequencing results. The average sequencing coverage was 350X, which provided sufficient power to detect somatic mutations with low variant allele frequency (VAF). Very high correlation was obtained for VAF between WGS and T200.2 sequencing (Pearson correlation = 0.963, Spearman correlation = 0.964). The somatic mutations in cancer-related genes identified by WGS were confirmed by T200.2 sequencing ([Figure S3I](#SD1){ref-type="supplementary-material"}). The copy number profiles in ovarian cancer genes identified in the T200.2 panel were also consistent with the WGS results. Specifically, *NF1* losses were identified in 58.3% of the R0, 20% of the NACT-ER, and 11.5% of the NACT-PR groups with the T200.2 panel, consistent with our WGS findings. We did not observe significant differences between CNVs in primary and metastatic sites, except those in the NACT-PR group; CNVs in *CDK12* were enriched in primary compared to metastatic sites (primary, 56%; metastases, 12%; p = 0.03).

Spectrums of Genomic Structural Rearrangement {#S7}
---------------------------------------------

Given the role of chromothripsis in cancer development ([@R22]; [@R34]; [@R77]), we next examined for chromothripsis-like patterns (CTLPs) and the status of telomere length (TL) across the groups. CTLPs were predicted and identified through copy number profiles for all samples. Examples of non-CTLPs and identified CTLPs are shown in [Figure S4A](#SD1){ref-type="supplementary-material"}. The number of copy number switches and log10 likelihood ratios (log10LRs) were calculated, and we identified CTLPs from 20 out of 75 samples. CTLPs in the R0 group showed fewer copy number switches and lower log10LRs, compared with the NACT-ER and NACT-PR groups ([Figures 3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}). In the R0 group, most CTLPs were detected on chromosomes 6 and 19, where *CCNE1*, *NOTCH3*, and *AKT2* are located. In the NACT groups, CTLPs were enriched on chromosomes 8 and 17, where *TP53* and *NF1* are located. In a parallel analysis, we also estimated the TLs for tumor and germline samples for each patient. To exclude the factors potentially affecting TLs other than cancer, the TL ratios of tumor versus germline were further calculated. Overall, the TL ratios were higher in the NACT-PR than in the NACT-ER and R0 groups, especially in primary tumors; these differences did not reach statistical significance ([Figure S4B](#SD1){ref-type="supplementary-material"}).

Prediction of Neoantigens Using WGS Data {#S8}
----------------------------------------

Given the importance of neoantigens derived from tumor-specific mutations in cancer immunity ([@R25]; [@R74]), we next identified and compared the numbers of neoantigens in each tumor sample by predicting the major histocompatibility complex (MHC) class I peptide binding affinity with somatic mutations from WGS analysis. According to predicted binding affinity, strong- and weak-binding neoantigens were identified. The median numbers of all neoantigens per sample identified were 99, 81, and 66 in the R0, NACT-ER, and NACT-PR groups, respectively ([Table S2](#SD3){ref-type="supplementary-material"}). The neoantigen levels were significantly higher in both the R0 (p = 0.023) and NACT-ER (p = 0.033) groups than in the NACT-PR group ([Figure S4C](#SD1){ref-type="supplementary-material"}). Furthermore, when excluding predicted weak-binding neoantigens, the median numbers of neoantigens identified were 16, 12, and 9 in the R0, NACT-ER, and NACT-PR groups, respectively. The R0 group showed a significantly higher level of strong-binding neoantigens than the NACT groups (p = 0.02; [Figure 3C](#F3){ref-type="fig"}). The difference was even more significant when considering only primary tumors (p = 0.01). Additionally, we analyzed the correlations between the neoantigen level and other features including mutation loads, CNV loads, CTLPs, and mismatch repair (MMR) CNVs ([Figure S4D](#SD1){ref-type="supplementary-material"}). A strong positive correlation was observed between the level of strong-binding neoantigens and mutation load (R = 0.68, p \< 0.0001), which is consistent within all three groups. We also observed some minor positive correlations between the neoantigen level with CNV load (R = 0.29, p = 0.013) and MMR CNVs (R = 0.3, p = 0.001). However, these minor positive correlations varied across patient groups.

Identification of Differentially Expressed Genes (DEGs) by RNA-Seq {#S9}
------------------------------------------------------------------

Next, we investigated gene expression differences among the R0, NACT-ER, NACT-PR, and NACT-ER/PR groups. Unsupervised hierarchical clustering was performed based on the 3000 most variable genes, and three main clusters were found across the groups ([Figure S5A](#SD1){ref-type="supplementary-material"}). We identified 206 DEGs from the comparison between the R0 and NACT-ER/PR groups ([Figure S5B](#SD1){ref-type="supplementary-material"}; [Table S3](#SD4){ref-type="supplementary-material"}). Of the 206 DEGs in the R0 versus the NACT-ER/PR groups, 67 were curated protein-coding transcripts (33 NM\_ or 1 XM\_) from NCBI RefSeq ([@R66]) ([Figure 4A](#F4){ref-type="fig"}); these included *POU3F3*, *NKX6--1*, and *PROK1*, which were upregulated in the R0 compared to the NACT-ER/PR group. Interestingly, differential expression of noncoding RNAs (ncRNAs) miR-7--2 (significantly upregulated) and miR-3142 (significantly downregulated) was seen in the R0 group compared to the NACT-ER/PR group ([Figure S5C](#SD1){ref-type="supplementary-material"}).

In the NACT-ER compared to the NACT-PR group, we observed 693 DEGs, including 263 curated protein-coding transcripts, with FDR \<0.1 and absolute L2FC \>2 ([Figure S5D](#SD1){ref-type="supplementary-material"}; [Table S3](#SD4){ref-type="supplementary-material"}). Consistent with our CNV data, we found that *NF1* mRNA was indeed significantly downregulated in the R0 (p = 0.03) compared to the NACT-ER/PR group ([Figure 4F](#F4){ref-type="fig"}), corroborating our findings of *NF1* CNV differences between the groups. Next, we identified 54 differentially expressed ncRNAs in the NACT-ER compared to the NACT-PR group and 14 DEGs between primary and metastatic tumors (FDR \< 0.1 and absolute L2FC \> 2) in all three groups ([Table S3](#SD4){ref-type="supplementary-material"}). Most DEGs were ncRNAs; only one predicted protein-coding transcript, *TBC1D27*, was significantly upregulated (p = 0.00002, q = 0.062) in the primary compared to metastatic sites for all three groups.

To understand the differences in potential biological functions and pathways among the R0, NACT-ER/PR, NACT-ER, and NACT-PR groups, we performed WebGestalt enrichment analysis of Gene Ontology (GO) using 206 DEGs among groups. GO terms for biological process (BP), cellular components (CC), and molecular function (MF) were significantly enriched in the NACT-ER/PR group versus the R0 group and in the NACT-ER group versus the NACT-PR group ([Figures S5E](#SD1){ref-type="supplementary-material"} and [S5F](#SD1){ref-type="supplementary-material"}); the top 10 enriched GO terms are listed in [Table S3](#SD4){ref-type="supplementary-material"}. Notably, in comparison of GO terms between the NACT-ER/PR and R0 groups, the number of DEGs was significantly enriched in BP, including the regulation of epithelial cell differentiation and activation of immune response. However, we did not observe significant cancer-specific-related GO terms in the comparison of the NACT-ER and NACT-PR groups. We also employed several web-based databases (KEGG, Kyoto Encyclopedia of Genes and Genomes; Reactome; and PANTHER, Protein ANalysis THrough Evolutionary Relationships) to identify enriched functional and signaling pathways using DEGs among the R0, NACT-ER, and NACT-PR groups ([Table S3](#SD4){ref-type="supplementary-material"}). Based on all DEGs between the R0 and NACT groups, we identified an enrichment of gene sets including cadherin signaling pathway; we also observed an enrichment of cell adhesion molecules, transcription misregulation in cancer, and the Notch signaling pathway, but these lacked statistical significance. Interestingly, we observed significant enrichment in GPCR (G protein-coupled receptor) downstream signaling, olfactory signaling, and signaling by GPCR in the DEGs between the NACT-ER and NACT-PR groups by Reactome pathway analysis.

Differential Analysis of Global Proteomic and Phosphoproteomic Data {#S10}
-------------------------------------------------------------------

Using a microscaled tandem mass tag (TMT)-MS-based proteomic/phosphoproteomic workflow, we quantified 7290 total proteins in 87 ovarian cancer specimens and 12,914 total phosphosites in 66 specimens from the 30 patients, among which 101 proteins were found to be significantly altered (adjusted p \< 0.05) in the NACT-ER/PR compared to the R0 groups ([Figure 4B](#F4){ref-type="fig"}; [Table S4](#SD5){ref-type="supplementary-material"}), which, based on principle component analysis (PCA), served to explain 29.9% and 5.7% of the variance between these groups ([Figure 4D](#F4){ref-type="fig"}). Signaling pathways supporting endocytosis, engulfment and cell spreading, and inhibition of cell death and RNA processing signaling were significantly altered in the NACT-ER/PR compared to the R0 group ([Figure S6A](#SD1){ref-type="supplementary-material"}). Among the significantly altered (p \< 0.01) putative drug and drug-associated signaling targets, we identified calcium-transporting ATP2C1 and STAT3 to be elevated and HDAC6, MGMT, and FDPS to be decreased in the NACT-ER/PR versus the R0 groups. Differential analysis identified 71 significantly altered (adjusted p \< 0.05) phosphosites in the NACT-ER/PR versus the R0 groups ([Figure 4C](#F4){ref-type="fig"}; [Table S4](#SD5){ref-type="supplementary-material"}) that, based on PCA, served to explain 29.3% and 9% of the variance between these groups ([Figure 4E](#F4){ref-type="fig"}). Pathway analyses of these altered phosphosites (p \< 0.01) revealed cell death of connective tissue cell signaling to be activated and the formation of the cytoskeleton to be inhibited in the NACT-ER/PR versus R0 groups ([Figure S6B](#SD1){ref-type="supplementary-material"}). Among the significantly altered phosphosites (p \< 0.05) in putative drug and drug-associated signaling targets, we identified S129 in SF3B1, S594 in FGA, and S706 in CD44 to be significantly elevated (p \< 0.05) in the NACT-ER/PR versus R0 groups. Notably, we validated transcript-level evidence at the protein level that *NF1* is significantly lower in abundance in the R0 versus NACT groups by both MS proteomics (p \< 0.0005) ([Figure 4G](#F4){ref-type="fig"}) and immunohistochemistry (IHC) assay (p \< 0.01) ([Figure 4H](#F4){ref-type="fig"}). In addition, significantly downregulated proteins that were idenified by TMT-MS analyses (i.e., MERLIN, moesin-ezrin-radixin-like protein; and ANNEXIN-1) were observed to have similar patterns of expression with the RPPA assay in the R0 compared to the NACT groups ([Figure S5G](#SD1){ref-type="supplementary-material"}; [Table S4](#SD5){ref-type="supplementary-material"}).

We identified 37 proteins as significantly altered (adjusted p \< 0.05) between the NACT-ER and NACT-PR groups ([Figure S6C](#SD1){ref-type="supplementary-material"}; [Table S4](#SD5){ref-type="supplementary-material"}) that, based on PCA, serve to explain 37.9% and 9.5% of the variance between these groups ([Figure S6D](#SD1){ref-type="supplementary-material"}). Pathway analyses of significantly altered proteins (p \< 0.01) revealed the activation of DNA metabolism and cytokinesis signaling and the inhibition of apoptosis and cellular senescence in the NACT-ER compared to the NACT-PR group ([Figure S6E](#SD1){ref-type="supplementary-material"}; [Table S4](#SD5){ref-type="supplementary-material"}). These data also revealed CDK4 to be significantly elevated (adjusted p \< 0.05) in the NACT-ER compared to the NACT-PR group. Fifty-nine phosphosites were significantly altered (adjusted p \< 0.05) between NACT-ER and NACT-PR tumor specimens ([Figure S6F](#SD1){ref-type="supplementary-material"}; [Table S4](#SD5){ref-type="supplementary-material"}) that, based on PCA, served to explain 42.1% and 7.2% of the variance between these groups ([Figure S6G](#SD1){ref-type="supplementary-material"}). Pathway analyses of these significantly altered phosphoproteomics data (p \< 0.05) showed that the frequency of tumor and genitourinary tumor signaling was activated while cell migration signaling was inhibited in NACT-ER compared to NACT-PR patient tumors ([Figure S6H](#SD1){ref-type="supplementary-material"}; [Table S4](#SD5){ref-type="supplementary-material"}). Significant decreases in phosphorylation of multiple tyrosine kinases---namely, Y426 and T427 on YES1, Y394 and T395 on LCK, Y420 and T421 on FYN, Y419 and T420 on SRC, and S4520 and S4523 on LRP1---were quantified in the NACT-ER compared to the NACT-PR group.

Immune Analysis {#S11}
---------------

We investigated whether different immune populations were associated with clinical characteristics of the tumors by immune profiling ([Figure S7A](#SD1){ref-type="supplementary-material"}) and observed significant differences among the groups in tumor area and all areas (tumor/non-tumor) ([Figures 5A](#F5){ref-type="fig"}, [5B](#F5){ref-type="fig"}, [S7B](#SD1){ref-type="supplementary-material"}, and [S7C](#SD1){ref-type="supplementary-material"}), as summarized in [Table S5](#SD6){ref-type="supplementary-material"}. We next focused on the percentage of T cell infiltration and found a significant increase in the number of infiltrated T cells in the R0 (2.91%) compared to the NACT-ER/PR group (1.35%, p = 0.0442) in tumor area ([Figure 5C](#F5){ref-type="fig"}). We further divided T cell populations into helper T cells (CD4^+^), cytotoxic T cells (CTLs; CD8^+^), and regulatory T cells (Tregs; FoxP3^+^ or CD8^+^FoxP3^+^) in tumor and all areas of each group. We did not find differences in helper T cells in any area among the groups. However, there was a significant increase in the percentage of CTLs in all areas in the R0 (2.51%) compared to the NACT-ER/PR group (1.04%, p = 0.0438) ([Figure S7D](#SD1){ref-type="supplementary-material"}). No statistical differences were observed in Tregs (CD8^+^FoxP3^+^) among the groups. However, the R0 group (0.25%) had a significantly lower classic Treg (FoxP3^+^) count than the NACT-ER group (0.89%, p = 0.0178) in the tumor area at the primary site only ([Figures 5D](#F5){ref-type="fig"} and [S7E](#SD1){ref-type="supplementary-material"}). Additionally, we observed significantly decreased macrophage counts (CD68^+^/163^+^ cells) in the tumor area in the R0 (4.33%) compared to the NACT-ER/PR (7.56%, p = 0.0063) and NACT-PR groups (9.07%, p = 0.0014) ([Figure 5C](#F5){ref-type="fig"}); the same pattern was also noted for all areas (tumor/non-tumor) ([Figure S7D](#SD1){ref-type="supplementary-material"}). Interestingly, macrophage counts were significantly lower in the tumor area of the primary site of the R0 (4.26%) compared to the NACT-ER/PR (9.21%, p = 0.024) and NACT-PR groups (11.09%, p = 0.0191) ([Figure 5D](#F5){ref-type="fig"}); the same pattern was seen for all areas as well ([Figure S7E](#SD1){ref-type="supplementary-material"}). Finally, we compared B cell populations among groups and found a trend toward significantly higher B cell infiltration in the tumor area of the NACT-PR (0.31%) compared to the NACT-ER group (0.04%, p = 0.0058) ([Figures 5C](#F5){ref-type="fig"} and [5D](#F5){ref-type="fig"}). Collectively, these results demonstrate significantly increased infiltrated T cells in the R0 compared to the NACT-ER/PR group and increased macrophages and B cells in the NACT-ER/PR and NACT-PR groups compared to the other groups.

Integrated Analysis of Multi-omics Data {#S12}
---------------------------------------

As a cross-validation, we inferred the composition of 22 immune cell types from the immune gene signature and the relative percentages of each type using RNA data ([Figure 6A](#F6){ref-type="fig"}). Using scores generated by CIBERSORT, we identified significantly different abundances of M2 macrophages (p \< 0.01) and monocytes (p \< 0.05) between the R0 and NACT-ER/PR groups ([Figure 6B](#F6){ref-type="fig"}). We also identified a significant difference in abundance of resting CD4 memory T cells (p \< 0.05) between primary and metastatic site tumors ([Figure 6C](#F6){ref-type="fig"}). An integrated analysis identified MARCO, SLC2A5 and HMGA2 as co-significantly altered (p \< 0.01) at the protein and transcript levels in the NACT-ER/PR compared to the R0 group ([Figure 6D](#F6){ref-type="fig"}). An integrated analysis identified KRT9 as significantly elevated (p \< 0.01) in the NACT-ER compared to the NACT-PR group at both the protein and transcript levels ([Figure 6E](#F6){ref-type="fig"}).

DISCUSSION {#S13}
==========

This is a report of high-depth multi-omics analysis of differences in molecular and cellular features of highly clinically annotated HGSC samples from primary and multiple metastatic sites. Our findings provide an understanding of the heterogeneity within HGSCs. Specifically, we found a significantly higher loss of the *NF1* gene, RNA and protein product copies, lower numbers of CTLPs, and a significantly higher level of strong-binding neoantigens in the R0 than in the NACT groups. We found significantly increased T cell infiltration and decreased numbers of macrophages in the R0 group and identified significant differences in transcriptomes and proteomes in this group.

While molecular analyses of HGSC have been performed previously ([@R5]; [@R7]; [@R64]; [@R81]), all such studies included samples only from those who underwent upfront debulking surgery. Moreover, the initial clinical management of those patients was highly variable. Here, we focused on testing primary and metastatic tumor samples from patients managed under a systematic surgical algorithm ([@R21]; [@R58]). With respect to the question of whether surgical effort resulting in R0 resection or underlying differences in tumor biology drive different clinical outcomes, our findings demonstrate that there are indeed substantial molecular and cellular differences in patients who underwent R0 tumor debulking compared to those triaged to receive NACT.

The biological mechanisms that might underlie *NF1*'s role as a biological marker for predicting R0 and NACT response are unknown. Although there is no prior report on the *NF1* CNV in prediction of R0 versus NACT groups in cancers, evidence suggests that NF1 plays an important role in the RAS/MAPK signaling pathway, tumorigenesis, and chemotherapy resistance in HGSC ([@R39]; [@R59]; [@R64]). Consistent with a significant loss of *NF1* CN and reduced CTLPs on chromosome 17, where NF1 is located, in the R0 group, we confirmed that the *NF1* mRNA and protein levels were also significantly decreased in the R0 compared to the NACT-ER/PR group.

Another potentially important finding was the significantly higher level of a strong-binding neoantigen signature in the R0 compared to the NACT group. The increase in neoantigens is associated with infiltration of tumor immune cells such as T cells ([@R53]; [@R74]). Importantly, we observed significantly more infiltrated T cells and fewer macrophages in the R0 compared with the NACT-ER/PR group and increased B cells in the NACT-PR compared to the NACT-ER group by immune assessments. Consistently, the deconvolution analysis using bulk RNA-seq data supported that there is a reduced macrophage cell population in the R0 compared to NACT-ER/PR group. Tumor-associated antigens have been considered for immunotherapeutic strategies, and a high correlation has been reported between tumor mutations and clinical benefits of immunotherapy targeting neoantigens in various solid tumors ([@R76]) and in preclinical studies ([@R24]; [@R36]). Importantly, we also identified significant differences in cancer-associated transcripts including ncRNAs ([@R12]; [@R44]; [@R86]; [@R93]) and significant proteome and phosphosite changes ([@R10]; [@R46]; [@R49]; [@R89]) in cancer-related and putative drug and drug-associated signaling targets among the groups in this study. Interestingly, significantly downregulated phosphosites of Src-family kinases, LCK, and YES1 were observed in the NACT-ER compared to the NACT-PR group; these have been implicated in supporting the maturation of developing T cell and migration signaling ([@R33]; [@R63]; [@R72]). Although further understanding of the clinical significance and validation of these transcript and protein alterations in ovarian cancer progression is required, such changes could serve as markers for the prediction of chemotherapy response in patients with HGSC.

Most patients with HGSC present with widely disseminated disease. Our findings from the clonal phylogenetic analyses support an ability to unravel complex events of metastatic dissemination and the early genetic divergence of metastatic lineages from the primary site in HGSC ([@R67]). Given the heterogeneity in response patterns to various therapies, it was unknown to what extent this could be explained by molecular differences between primary and metastatic sites. A case report previously reported intra-patient tumor heterogeneity in immune microenvironments in patients with HGSC ([@R30]). Interestingly, we found no significant genomic variations between primary and metastatic sites, implying that the biological processes underlying complex genomic instability, including CNV and SV, likely occur at an early point in the disease progression. Interestingly, nonsense mutations of *CSMD3* and *PIK3CA*, frequently detected in HGSC ([@R7]) and in other types of ovarian cancers ([@R37]), were detected exclusively in the NACT-PR and not the NACT-ER or R0 groups. However, neither of these gene mutations has been investigated in HGSC in the context of chemotherapy response and clinical outcome.

Overall, more accurate predictors could lead to precise surgical therapy strategies; if verified, our discoveries in this study---molecular, protein, and immune signatures between various HGSC subgroups---may enhance the prediction of R0 resection and have prognostic and therapeutic implications for patients with HGSC.

STAR★METHODS {#S14}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S15}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be addressed by the Lead Contact, Anil K. Sood (<asood@mdanderson.org>). No reagents were generated in this study.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S16}
--------------------------------------

### Patients {#S17}

This study was approved by the Institutional Review Board of The University of Texas MD Anderson Cancer Center, and all samples were collected after obtaining written informed consent from patients. Patients with suspected advanced primary ovarian cancer underwent a laparoscopic assessment to determine a metastatic disease burden score (modified Fagotti score) ([@R18]; [@R21]) and acquire tissues ([Figure 1A](#F1){ref-type="fig"}). We obtained fresh frozen tumor specimens from the MD Anderson Gynecologic Tumor Bank for 30 patients diagnosed with HGSC who had available a primary site specimen, two metastatic site specimens and matched blood samples obtained upon laparoscopic assessment. Following laparoscopic assessment, patients with predictive index value \< 8 underwent primary tumor reduction surgery, and patients with predictive index value ≥ 8 underwent NACT followed by interval cytoreduction surgery. We selected 10 patients with no visible residual disease after primary surgery (R0), 10 with poor response to NACT with carboplatin and paclitaxel (NACT-PR) and 10 with excellent response to NACT (NACT-ER) ([Figure 1B](#F1){ref-type="fig"}). Patients' demographic and clinical characteristics are described in [Table S1](#SD2){ref-type="supplementary-material"}. Response to NACT was considered poor if patients had stable or progressive disease after 3--4 cycles upon radiology evaluation and/or suboptimal interval cytoreduction after NACT according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Response to NACT was considered excellent if there was a complete response or only microscopic disease left at the time of interval surgery and/or pathology from interval surgery. Tumor biopsies and matched blood samples from the 30 patients were subjected to analyses ([Figure 1C](#F1){ref-type="fig"}).

METHOD DETAILS {#S18}
--------------

### Whole-genome sequencing {#S19}

Genomic DNA from 90 frozen tumor tissues from 30 patients (one primary site and two metastatic sites per patient) and matched blood samples as germline controls were prepared by the Biospecimen Extraction Resource of MD Anderson Cancer Center. In brief, genomic DNA was extracted from frozen tissues and blood using the QIAamp DNA Mini Kit and QIAamp DNA Blood Mini Kit (-QIAGEN), respectively, following the manufacturer's instructions. Extracted genomic DNA was accurately quantified using Quant-iT PicoGreen dsDNA reagent and kit with a Qubit 3.0 Fluorometer (Invitrogen). DNA libraries were prepared using a TruSeq DNA PCR-Free Library Prep Kit (Illumina) following the manufacturer's instructions. Briefly, genomic DNA was diluted to 20 ng/mL using Resuspension Buffer (RSB, Illumina), and 55 mL was transferred to microTUBES (Covaris). The normalized genomic DNA was then sheared on an LE220 focused-ultrasonication system (Covaris) to achieve a target peak of 450 bp with average power of 81.0 W (So-noLab settings: duty factor, 18.0%; peak incident power, 45.0 W; 200 cycles per burst; treatment duration, 60 s; water bath temperature, 5°C -- 8.5°C). The quality of the final DNA libraries was assessed with a High Sensitivity dsDNA Kit (Advanced Analytical Technologies, Inc.). Per the manufacturer's protocol, the library peak size was in the range of 550 to 620 bp. The DNA libraries were quantified by real-time quantitative PCR, using the KAPA SYBR FAST Library Quantification Kit (KAPA Biosystems) optimized for the LightCycler 480 instrument (Roche). DNA libraries were then normalized to 2 nM and clustered on the Illumina cBot 2 at 200 pM using a HiSeq X v2 flow cell and the HiSeq X HD Paired-End Cluster Generation Kit v2. Paired-end sequencing was performed with the HiSeq X HD SBS Kit (300 cycles) on the Illumina HiSeq X.

### Tumor purity and WGS data analysis {#S20}

Samples with low tumor purity (\< 75% proportion of cancer cells) were excluded from the estimation of tumor sample purity by WGS results after purity filtering. Therefore, 75 tumor samples with a high level of purity from 28 patients (9 R0 group patients, 9 NACT-ER and all 10 NACT-PR) were incorporated into the downstream analysis of WGS data. Pair-end sequencing reads in "fastq" format were generated from BCL raw data using Illumina CASAVA (Consensus Assessment of Sequence and Variation) software. The reads were aligned to the hg19 human reference genome using the BWA software package ([@R43]) followed by removal of the duplicate reads using Picard tools (<http://broadinstitute.github.io/picard/>), and local realignments were performed using the GATK toolkit ([@R54]). The BAM files were then used for downstream analysis.

### Somatic mutation detection {#S21}

The MuTect method ([@R11]) was used to identify somatic point mutations, and the Pindel tool ([@R91]) was used to identify somatic insertions and deletions. A series of post-calling filtering algorithms were applied for somatic mutations: (a) total read count in tumor sample ≥ 20, (b) total read count in germline sample ≥ 10, (c) VAF (variant allele frequency) ≥ 0.05 in tumor sample and ≤ 0.02 in matched normal sample and (d) population frequency threshold of 1% for filtering out common variants in the databases dbSNP129 ([@R71]), 1000 Genomes Project ([@R1]), Exome Aggregation Consortium ([@R42]) and ESP6500 ([@R23]).

### Clonal population estimation in tumors {#S22}

The Sequenza package ([@R20]) was used to estimate tumor cellularity and ploidy and to calculate an allele-specific copy number profile for each sample. The PyClone model ([@R70]) was used to identify and quantify clonal populations in tumors. Mutant-allele tumor heterogeneity (MATH) scores were calculated as a measurement of intratumor genetic heterogeneity ([@R52]; [@R57]). To construct phylogenetic trees, functional mutations were converted into binary format, with 1 being mutated and 0 otherwise. Ancestors were germline DNA, assuming no somatic mutations, while germline mutations in *BRCA1/2* were included. Phylogenetic trees were constructed using the multistate discrete-characters Wagner parsimony method using the PHYLIP program ([@R68]). The trees were redrawn with relative trunk and branch lengths proportional to the number of mutations for visualization purposes.

### Copy number variation and structure variation detection {#S23}

CNVs were identified using HMMcopy ([@R26]). The copy number log2 ratios of tumor versus matched normal samples were calculated and then subjected to segmentation using circular binary segmentation ([@R62]). A cutoff of log2 ratio \< −0.4 was applied to identify copy losses, and log2 ratio ≥ 0.4 was applied for copy gains. Copy number signatures were identified based on the components described in the CNsignatures algorithm ([@R51]). SVs were called by three methods: LUMPY ([@R40]), BRASS (<https://github.com/cancerit/BRASS>) and BreakDancer ([@R19]). The SVs that appeared in normal samples were filtered out. To reduce false-positive rates, only SVs identified by at least two methods were kept. SV signatures for ovarian cancers were calculated, as described previously ([@R28]). Chromothripsis-like patterns were identified by the CTLPScanner server ([@R90]) with the filtering of: (a) number of copy number switches ≥ 20 and (b) log10 likelihood ratio ≤ 8.

### High-depth targeted sequencing analysis {#S24}

We performed high-depth targeted sequencing (T200.2 panel) as previously described ([@R8]), and genomic DNA from each sample was prepared as described above for WGS. Briefly, the aliquots of genomic DNA were re-quantified by PicoGreen (Invitrogen) and quality was assessed using a 2200 TapeStation system (Agilent). Then genomic DNA was sheared by sonication using a Covaris E220 instrument with the following conditions: pPeak incident power, 175 W; duty cycle, 20%; intensity, 5; cycles per burst, 200; and 120 s. To ensure the proper fragment size, samples were checked on TapeStation using the High Sensitivity DNA Kit (Agilent). The sheared DNA proceeded to library prep using a KAPA Hyper Prep Kit following the "with beads" manufacturer protocol. PCR primers were removed by using 1.8x volume of Agencourt AMPure PCR purification kit (Agencourt Bioscience Corporation). At the end of the library prep, samples were analyzed on TapeStation to verify correct fragment size and to ensure the absence of extra bands. Samples were quantified using a KAPA qPCR Quantification Kit (KAPA Biosystems). Equimolar amounts of DNA were pooled for capture (2--6 samples per pool). Equimolar amounts of DNA were pooled for capture (8--16 samples per pool). Global copy number selected areas were also captured. We selected for capture 323 genes that are clinically relevant in cancer on the basis of mutational data and the COSMIC database ([@R4]) and TCGA. Global copy number selected areas were also captured. We designed biotin-labeled probes with Roche NimbleGen for capturing target regions (all exons in those 323 genes plus copy number regions) and followed the manufacturer's protocol for the capture step. The captured libraries were sequenced in 100-bp paired-end mode using a HiSeq 2000 system (Illumina) on a TruSeq v3 paired-end flow cell, according to the manufacturer's instructions, at a cluster density of 700--1000K clusters/mm^2^. Sequencing was performed on a HiSeq 2000 for 2 × 100 paired end reads with a 7 nt read for indexes using Cycle Sequencing v3 reagents (Illumina). The resulting BCL files containing the sequence data were converted into ".fastq.gz" files and individual libraries within the samples were de-multiplexed using CASAVA 1.8.2 with no mismatches. All regions were covered by \> 20 reads.

### Telomere length estimation and comparison among groups {#S25}

TL was estimated with TelSeq software ([@R14]) for both tumor and normal samples for each patient. To exclude the factors that affect telomere length other than cancer, the TL ratio was further calculated as log2 (TL_tumor/TL_normal). TL ratios were compared among the R0, NACT-ER and NACT-PR groups using the Wilcoxon signed-rank test.

### Neoantigen prediction in tumors {#S26}

Neoantigens were predicted based on somatic mutations, including both SNVs and InDels. The binding affinity was predicted by the NetMHCcons server ([@R32]). For any neoantigens, the binding affinities were predicted for all MHC types. For each MHC type, binding affinities were predicted on both wild-type and mutant sequences. The peptide was identified as a strong binder if the %Rank (rank of the predicted affinity compared to a set of 400.000 random natural peptides) was below 0.5% or the binding affinity (IC~50~) was below 50. The peptide was identified as a weak binder if the %Rank was between 0.5% and 2% or the binding affinity (IC~50~) was between 50 and 500. Here, we only included the neoantigens that showed weak and strong binding in the mutant but not the original wild-type sequence. The numbers of weak- and strong-binding neoantigens were compared between patient groups. The Wilcoxon rank sum test was used to determine whether there were statistically significant differences between groups.

### RNA sequencing analysis {#S27}

RNA sequencing (RNA-seq) was performed in the MD Anderson Cancer Genomics Core Laboratory as previously described ([@R48]). Total RNA from 89 frozen tissues from 30 patients was prepared, and the capture step was performed using whole-exome biotin-labeled probes from Roche NimbleGen (Exome V3) and following the manufacturer's protocol; the remaining sample did not have an adequate amount of tissue. Total RNA was quantified by PicoGreen (Invitrogen), and quality was assessed using a 2200 TapeStation system (Agilent). RNA from each sample (10--100 ng) was converted to double-stranded cDNA using an Ovation RNA-Seq System V2 kit (NuGEN). The cDNA library was prepared as described above for high depth sequencing, and we used whole-exome biotin-labeled probes from Roche NimblegGn (Exome v3.0) and followed the manufacturer's protocol for the capture step. Sequencing proceeded as described above for the high depth sequencing analysis.

Sequencing proceeded as described above for the high-depth sequencing analysis. Raw RNA-sequencing data of 89 samples were converted to fastq files and aligned to the reference genome (hg19) using the Spliced Transcripts Alignment to a Reference (STAR) algorithm ([@R15]), and the reads quality was evaluated with FastQC and Qualimap tool ([@R60]). RNA-seq data were excluded for the 15 out of 89 samples with low tumor purity as estimated by WGS; the remaining 74 samples were subjected to downstream analysis. The R package DESeq2 was used for data processing, normalization and differential expression analysis following standard procedures ([@R50]). Each gene-level htseq-count table contained the read counts of 57,798 genes with gene_ids. The gene counts were normalized using the scaling factor method in DESeq2. If the number of over-lapping reads of any given gene was less than 1 per million total mapped reads for all samples, this gene was excluded from further analysis. In this way, 25,841 (44.7%) genes were removed. An unsupervised hierarchical clustering analysis was performed using the Pearson correlation coefficient as the distance metrics and the Ward's linkage rule using the 3000 genes with the largest standard deviations (SD). DESeq2 was used to identify the differentially expressed genes (DEGs) and calculate the FDR, and a cutoff of absolute log2-fold change (L2FC) \> 2 and FDR \< 0.1 were used to define the DEGs. Functional analyses and pathway analyses were further performed using a Web-based gene set analysis toolkit (WebGestalt) ([@R83]; [@R92]) with the DEGs lists obtained from DESeq2 for gene ontology (GO) analysis. Pseudogenes and noncoding RNAs were excluded from the anlyses. Functional annotations were based on the GO database, including the biological process, cellular component and molecular function. Pathway analyses were based on multiple databases: KEGG (<https://www.kegg.jp/>), Reactome (<https://reactome.org/>) and PANTHER (<http://www.pantherdb.org/>). The overrepresentation enrichment analysis was used to evaluate the enrichment of functional groups and pathways.

### Reverse phase protein array (RPPA) analysis {#S28}

To collect protein expression data, a Reverse Phase Protein Array (RPPA) assay was performed at the MD Anderson Functional Proteomics Reverse Phase Protein Array (RPPA Core, as described previously ([@R9]; [@R45]; [@R47]; [@R84]) using 81 frozen tumor tissues from patients; the remaining 9 samples did not have an adequate amount of tissue. We also examined the phosphorylation status of proteins using antibodies specific to particular proteins or phosphorylated forms of proteins because the majority of antibodies used in RPPA analyses are preselected for signaling pathways that are well known to be involved in tumor development. The samples were probed with 297 antibodies in total. The signal intensities on the RPPA arrays were quantitated using MicroVigene software (VigeneTech) and processed using the R package Super-Curve (version 1.01; <https://bioinformatics.mdanderson.org/public-software/archive/oompa/>), which generated the relative log2 expression value for each protein.

Protein levels for each sample were determined by interpolating each dilution curve produced from the densities of the 5-dilution sample spots using SuperCurve software. All relative protein levels were normalized for protein loading, transformed to linear values and log2-transformed. The 14 samples with low tumor purity were excluded from further downstream analyses. A mixed-effect model was fit to each normalized protein level with response group and tissue type as main-effect covariates and patients as the random effect covariate. We used t tests to test against the null hypothesis of no difference in protein expression between any two groups. The Benjamini-Hochberg method was used to control the FDR. Next, protein network analysis was performed on 16 differentially expressed proteins using the GeneMANIA server ([@R85]). The nodes in the resulting network represent the proteins, and the edges represent the protein-protein interactions. Four types of direct interactions were selected to build the network: physical interactions, co-localization, pathway and genetic interactions. The network edges were weighted by the corresponding data source with the adaptive network weighting method by GeneMANIA.

### Specimen preparation for proteomics {#S29}

Laser microdissection was used to harvest whole tissue representations (cancer and stroma combined) of each specimen, which were digested with trypsin using pressure cycling technology (PCT, Pressure Biosciences, Inc.) from 87 frozen tissues from 30 patients. Briefly, tissue specimens were sectioned (8 μm) by microtome onto polyethylene naphthalate membrane slides and hematoxylin-eosin stained. Laser microdissection was utilized to harvest whole tissue representations of each specimen (cancer and stroma combined) prior to proteomic sample preparation, with a minimum selected total area goal of 65,000,000 μm^2^ from 8 μm thick sections, avoiding areas of necrosis and blood. The laser-microdissected harvests were collected directly into microcentrifuge tubes containing 50 μL liquid chromatography (LC)/mass spectrometry (MS)-grade water for proteomic analysis. Tissue specimens were stored in a −80° C freezer until sample preparation. Tissue harvests were transferred to a Pressure Cycling Technology (PCT, Pressure BioSciences, Inc) microtube containing 20 μL of 100 mM triethylammonium bicarbonate (TEAB), 10% acetonitrile. The samples were incubated at 99° C for 30 min followed by 50° C for 10 min. Tissues were digested by adding SMART trypsin (Ther-moFisher Scientific Inc) at a ratio of 1 μg per 30,000,000 μm^2^ tissue by employing PCT, where each sample was cycled 60 times between 45,000 psi for 50 s and atmospheric pressure for 10 s at a constant temperature of 50° C. Each protein digest was transferred to a clean 0.5 mL microcentrifuge tube, vacuum dried, and re-suspended in 50 μL 100 mM TEAB. Final digest recoveries were determined by colorimetric assay (Pierce BCA Protein Assay Kit). Peptide (50 mg) from each sample was labeled with a unique isobaric tandem mass tag (TMT) label according to the manufacturer's instructions (TMT-11-plex Isobaric Label Reagent Set, ThermoFisher Scientific). A reference sample, generated by pooling equivalent amounts of peptide digests from each of the patient samples in the cohort, was labeled with TMT "Channel" 126 and included in each TMT-11-multiplex (e.g., reference standard Channel 126 + 10 unique samples occupying Channels 127N-131). Each TMT-11 multiplex set of clinical samples was constructed in a randomized fashion. After quenching, each TMT-11 multiplex set of samples was combined and vacuum dried to approximately 80 mL.

### Basic reversed-phase liquid chromatographic (bRPLC) fractionation {#S30}

Each TMT-11 multiplex set of samples was loaded onto a C-18 trap column in 10 mM NH~4~HCO~3~ (pH 8.0) and fractionated by bRPLC into 96 fractions through development of a linear gradient of acetonitrile (0.69% acetonitrile/min). Thirty-six concentrated fractions were generated by pooling the samples in a serpentine manner. Ten percent (volume) of each fraction was removed for liquid chromatography-tandem mass spectrometry (LC-MS/MS). The remaining 90% (volume) of the 36 fractions was pooled into 12 fractions for serial phosphopeptide TiO~2~ enrichment followed by iron immobilized metal ion affinity chromatography (Fe-IMAC). Briefly, peptide fractions were vacuum dried, re-suspended in TiO~2~ binding/equilibration buffer and bound to TiO~2~ affinity spin tips (High-Select TiO~2~ Phosphopeptide Enrichment Kit, Thermo Fisher Scientific), and sample flow-through and washes were reserved for subsequent enrichment by Fe-NTA (nitrilotriacetic acid) affinity chromatography (High-Select Fe-NTA Phosphopeptide Enrichment Kit). As a quality control analyses, we investigated the enrichment of phosphotyrosine-containing peptides resulting from this dual enrichment strategy and found that we recover these at a very similar relative level (1.3%) as to similar dual enrichment strategies employed previously, such as from the Mann lab where they observed 1.8% phosphotyrosyl-containing peptides ([@R61]). Notably, tissue samples organized in TMT sample plexes 11 through 14 exhibited low overall peptide yields and were thus analyzed using fewer concatenated peptide digest fractions, i.e., 12 fractions for plexes 11 through 13 and 24 fractions for plex 14 relative to the 36 total fractions analyzed for global proteomics across sample plexes 1 through 10. As sample yields were below SOP expectations for sample plex 11 through 14, phosphopeptide analyses for the samples were omitted from data analyses downstream.

### LC-MS/MS proteomics {#S31}

The TMT-11 sample multiplex bRPLC fractions (36 total fractions for global proteomics and 12 fractions for phosphopeptides serially enriched by TiO~2~ and Fe-IMAC) were analyzed by LC-MS/MS employing a nanoflow LC system (EASY-nLC 1200, Thermo Fisher Scientific) coupled online with an Orbitrap Fusion Lumos Tribrid mass spectrometer (Thermo Fisher Scientific). In brief, each sample (5 mL) was loaded on a nanoflow high-performance LC system outfitted with a reversed-phase trap column (Acclaim™ PepMap™ 100 C18, 2 cm length, nanoViper Trap column, Thermo Fisher Scientific) and a heated (50°C) reversed-phase analytical column (Acclaim™ PepMap™ RSLC C18, 2 μm, 100Å, 75 μm × 500 mm, nanoViper, Thermo Fisher Scientific) connected online with an Orbitrap mass spectrometer. Peptides were eluted by developing a linear gradient of 2% mobile phase B (95% acetonitrile with 0.1% formic acid) to 32% mobile phase B within 120 min at a constant flow rate of 250 nL/min. High-resolution (R = 60,000 at *m/z* 200) broadband (*m/z* 400--1600) mass spectra (MS) were acquired, from which the top 12 most intense molecular ions in each MS scan were selected for high-energy collisional dissociation (HCD, normalized collision energy of 38%) acquisition in the Orbitrap at high resolution (R = 50,000 at *m/z* 200). Monoisotopic precursor selection mode was set to "Peptide," and MS1 peptide molecular ions selected for HCD were restricted to z = +2, +3 and +4. The radio frequency (RF) lens was set to 30%, and both MS1 and MS2 spectra were collected in profile mode. Dynamic exclusion (t = 20 s at a mass tolerance = 10 ppm) was enabled to minimize redundant selection of peptide molecular ions for HCD.

### Quantitative Proteomic Data Processing Pipeline for Global and phosphoproteome analyses {#S32}

Peptide identifications were generated by searching the .raw data files with a publicly available, non-redundant human proteome database (Swiss-Prot, *Homo sapiens* \[<https://www.uniprot.org/>, downloaded 12/01/2017\]) appended with porcine trypsin (Uniprot: P00761) and iRT peptide ([@R17]) sequences using Mascot (Matrix Science) and Proteome Discoverer (Thermo Fisher Scientific) software. The .raw data files corresponding to each LC-MS/MS injection per TMT-11 multiplex were searched using the following parameters: precursor mass tolerance of 10 ppm, fragment ion tolerance of 0.05 Da, a maximum of two tryptic miscleavages, static modification for TMT reporter ion tags (229.1629 Da) on N-termini and lysyl residues, and dynamic modifications for oxidation (15.9949 Da) on methionine residues, as well as phosphorylation (79.9663 Da) on seryl, threonyl or tyrosyl residues for phosphoproteome analyses. The resulting peptide spectral matches (PSMs) were filtered using an FDR \< 1.0% (q-value \< 0.01), as determined by the Percolator ([@R31]) module of Proteome Discoverer. Phosphoproteome search results were further analyzed by the ptmRS node ([@R80]) within Proteome Discoverer as a confidence measure for the post-translational modifications identified. TMT reporter ion intensities were extracted using Proteome Discoverer at a mass tolerance of 20 ppm, and PSMs lacking a TMT reporter ion signal in TMT channel *m/z* 126 (TMT-126, the pooled study reference combined from all patient sample digests), PSMs lacking TMT reporter ion intensity in all TMT channels, or PSMs exhibiting an isolation interference of ≥ 50% were excluded from downstream analyses. Log~2~-transformed TMT reporter ion ratios corresponding to individual patient tissue samples were calculated for each PSM against the pooled reference standard (TMT-126 channel). Log~2~-transformed PSM abundance distributions were normalized by calculating the mode-centered z-score transformation adapted from previous study ([@R55]), for each channel in the TMT-11 multiplex as follows: normalized PSM (Log~2~Ratio) = \[PSM (Log~2~Ratio) -- ModeCenter PSM (Log~2~Ratio) / s PSM (Log~2~Ratio). Briefly, this method normalizes log-transformed PSM abundances for each patient sample channel by calculating the mode log ratio as well as the standard deviation for the entire distribution of PSMs quantified in a patient sample channel. The log ratio intensity of each PSM quantified for a given patient channel is then normalized by subtracting the mode log ratio and then dividing by the standard deviation of all PSMs quantified for a given PSM per patient channel. For global protein-level abundance, the abundances of proteins identified by a unique PSM (i.e., in which a PSM maps uniquely to a single protein accession) were determined by calculating the median log~2~-transformed abundance ratios of all such PSMs. The abundances of PSMs mapping to multiple proteins (i.e., "multi-mapper" PSMs) were compared to mapped unique protein abundances using a mean-squared-error approach to assign them to unique proteins based on comparative abundance analyses. Briefly, mean squared log~2~-transformed abundance ratios ([@R2]; [@R79]) were calculated for multi-mapper PSMs with intensity data observed in R 50% of all TMT channels for a given TMT sample plex; redundant and multiply charged versions of a given PSM were considered unique biochemical events. Multi-mapper PSMs were assigned to the corresponding unique protein accessions exhibiting the smallest difference in relative abundance levels comparatively. Multi-mapper PSMs mapping to protein accessions not identified by any unique PSMs were excluded from downstream analyses. This strategy leverages quantitative data collected for unique peptides (in this case 95.2% of total PSMs identified against the non-redundant SwissProt human proteome database that we searched our data against) to identify parent proteins of co-measured non-unique peptides (in this case representing 4.8% of total PSMs identified). Protein-level abundance was calculated from normalized, median log~2~-transformed TMT reporter ion ratio abundances from a minimum of two PSMs corresponding to a single protein accession. The performance of a subset of six patient samples labeled as independent technical replicate channels was assessed by direct comparison of proteins co-quantified between replicate samples; all patient samples exhibited Spearman Rho \> 0.85 ± 0.03 except replicates for patient sample PR-R0-4-1 (R = 0.52) which was thus removed from consideration in downstream analyses. Normalized log~2~-transformed protein-level abundances for each TMT-11 multiplex were merged, and protein-level abundances for proteins not quantified in all patient samples, but in ≥ 50%, were imputed using a k-nearest neighbor (k-NN) strategy adapted from previous publication ([@R55]) using the pamr (Prediction Analysis for Microarrays) R package ([@R41]). The abundances of phosphorylated (phospho)-PSMs were assembled at the level of discrete phosphosites that map to a unique protein using a tiered strategy aimed at defining high- and low-confidence phospho-PSMs. First, TMT reporter ion intensities were processed for phospho-PSMs as described above to calculate normalized, log~2~-transformed abundance ratios of phospho-PSMs for a given patient sample. Phospho-PSMs that mapped to unique proteins were assigned to those protein identifiers. Multi-mapper phospho-PSMs were assigned to all proteins that were co-identified in companion global proteome data. Multi-mapper phospho-PSMs that did not map to a unique protein in global proteomic data were assigned to the first protein accession that a given phospho-PSM was assigned to by database search. The number and amino acid positions of phosphosites that were identified in the database search for a given phospho-PSM were compared with phosphosite positions predicted by the ptmRS algorithm. A high-confidence phospho-PSM was determined when all phosphosites identified by database search also exhibited \> 50% probability of being the "best" predicted phosphosite for a given phospho-PSM. A low-confidence phospho-PSM was determined when any phosphosite identified by database search was not predicted as a phosphosite or exhibited \< 50% probability of being predicted as the "best" phosphosite. Low-confidence phospho-PSM candidates were further prioritized using a tiered strategy in which unique phosphosite variants identified for the same phospho-PSM event were selected based on the highest ptmRS probability score that exhibited the lowest search engine rank in the TMT-11 patient sample plex with the greatest number of total PSMs. Normalized log~2~-transformed protein-specific phosphosite abundances were determined by calculating the median abundance of phospho-PSMs exhibiting the same phosphosite as well as methionine oxidation state. Phosphosites quantified redundantly as both low- and high-confidence versions were further filtered to prioritize only high-confidence phosphosites for downstream analyses. For phosphosites co-identified in companion global proteomic data, median log~2~-transformed, protein-specific phosphosite abundances were also normalized to the total protein abundance quantified in global proteome analyses.

### Differential analyses of global and phosphosite data {#S33}

Differential analyses of neurofibromin (NF1) global protein abundance were performed using Mann-Whitney U rank sum testing in MedCalc (version 19.0.3). Phosphosite data were filtered prior to differential analyses so that phosphosites were measured in ≥ 50% of the comparator cohort, i.e., NACT-ER versus NACT-PR and NACT-ER/PR versus R0 patients. Differential analyses of global and phosphosite TMT-11 data matrixes were performed for patient samples of interest using the LIMMA package (version 3.8) ([@R69]) in R (version 3.5.2). Phosphosite data were pre-filtered for protein and phosphosite alterations passing LIMMA adjusted p value \< 0.05; these alterations were prioritized for downstream analyses. Significant protein and phosphosite alterations were visualized in heatmaps and by principle component analysis (PCA) using default settings in the ClustVis web tool ([@R56]). To investigate the impact of imputation on significantly altered protein features used for principle component analyses, we reviewed proteins significantly altered between NACT-ER/PR versus R0 patients (n = 104) and find that 53 of these alterations were imputed in as few as two and as many as forty-five cases across our patient cohort (n = 87). We performed PCA analyses of the 51 non-imputed protein alterations among this list and compared variances for this limited feature set for the first two principle components (PC1 = 33.9% and PC2 = 6.8%) relative to variance observed for the 104 total protein alterations ([Figure 4D](#F4){ref-type="fig"}, PC1 = 29.6% and PC2 = 5.4%), between NACT-ER/PR versus R0 patients. We find these variances to not be significantly different (MWU p = 0.667). Functional inference analyses were performed for significantly altered proteins and phosphosites (significance defined as LIMMA p value \< 0.01 and exhibiting a log2 fold-change cut-off ± 1.5 proteins) using Ingenuity Pathway Analysis. Significantly enriched diseases and biofunctions predicted to be activated or inhibited were prioritized for further analyses. This strategy was intended to expand the feature set to investigate overarching signaling and pathway alterations between these patient cohorts.

### Data analysis of targeted sequencing {#S34}

A customized pipeline was applied to analyze the high-depth targeted sequencing results, which was adopted from tools that are applied to cancer genome sequencing projects such as TCGA but implemented with further optimization for deep clinical sequencing, as we previously described ([@R8]). Briefly, we aligned the reads to human reference assembly hg19 using BWA and Picard ([@R13]). We then used the MuTect and Pindels algorithms against a pooled common normal reference to call high-confidence mutations. The same public databases as described in WGS analysis were used to further remove the germline polymorphism with a population frequency cutoff of 0.5%. Copy number alterations were identified using an in-house R package as previously described ([@R78]). A cutoff of log2 ratio ≤ −0.4was applied to identify copy losses and log2 ratio ≥ 0.4 was applied for copy gains.

### Immunohistochemical analysis {#S35}

50 paraffin sections from the R0 (n = 24) and NACT-ER/PR (n = 26) groups were used for the validation of NF1 protein expression by immunohistochemistry assay (IHC), and IHC was performed in the MD Anderson Research Histology Core Laboratory. Briefly, the slides were incubated with a primary antibody Neurofibromin 1 (1:150, Abcam) for 8 minutes, and then detected using Leica Bond Polymer Refine Detection Kit according to manufacturer's instuctions (Leica Biosystems). The quantification of NF1 protein expression by IHC in the FFPE sections, each slide was independently evaluated and scored by three independent investigators including a board-certified pathologist on blinded samples according to expression level scoring matrix ([Figure S8](#SD1){ref-type="supplementary-material"}), and NF1 expression score (H-score, range 0--300) was determined by multiplying the percentage of positive cells.

### Immune-profiling analysis {#S36}

Opal multiplex staining was performed for immune infiltrate analysis. In brief, Opal multiplex allowed for the simultaneous evaluation of seven markers (CD4, CD8, CD20, FoxP3, cytokeratin, CD68/163 and DAPI) in a single tissue section. Multispectral imaging was applied to the seven-marker stained samples. An average of five representative images per tissue sample was obtained. After image capture, spectral unmixing was performed to separate raw images into individual fluorophores. The spectrally unmixed images were then analyzed to identify different cellular phenotypes, which allowed for the evaluation of the regulatory T cell population identified by CD8^+^FoxP3^+^ positivity ([Figure S7A](#SD1){ref-type="supplementary-material"}). All other cells not defined by our phenotyping categories (blood vessels, nerves) were grouped into an "other" category. Finally, tumor epithelial versus non-tumor areas of each specimen were distinguished using a tissue segmentation algorithm. After cell phenotyping, comparisons were drawn between abundance and distribution of immune infiltrates for the R0 (n = 25, 10 primary and 15 metastatic sites), NACT-ER/PR (n = 28), NACT-ER (n = 14, 5 primary and 9 metastatic sites) and NACT-PR (n = 14, 5 primary and 9 metastatic sites) groups.

### Inference of immune cell populations {#S37}

We estimated the immune contextures of 74 samples using the CIBERSORT tool (<https://cibersort.stanford.edu>). We used its original algorithm to infer the fractions of 22 immune cells relative to the total immune-cell population. In addition, we also applied its absolute mode to calculate a score that quantitatively measured the overall abundance of each cell type. A mixed-effect model was fit to a score with response group and tissue type as main-effect covariates and patients as the random effect covariate.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S38}
---------------------------------------

The analysis of tumor samples with matched normal samples allowed for the detection of somatic genomic events contributing to the observed differential response to treatment between groups, and the analysis of multiple sampling per patient enabled us to assess clonal and adaptive evolution in different response groups. To evaluate the statistical significance, Student t test is used if the data fits normal distribution. Otherwise, Wilcoxon rank-sum test is used to test the differences between groups. BH method is used to control the false discovery rate. In transcriptomic analysis, the differential expression was evaluated using a negative binomial generalized linear model as described in DESeq2 ([@R50]), and logarithmic fold change and adjusted p values were used for differentially expressed gene assessment. In the proteomic analysis, the differential expression was evaluated by the linear model described in LIMMA ([@R69]). The statistical significance of differences (p \< 0.05) on infiltrated immune cells between groups was determined using the Student t test (GraphPad Prism).

DATA AND CODE AVAILABILITY {#S39}
--------------------------

Sequence data from the WGS, deep targeted sequencing and RNA sequencing in this study have been deposited in the European Genome-phenome Archive (EGA, <https://www.ebi.ac.uk/ega/home>) under accession numbers EGAD00001005240, EGAD00001005239 and EGAD00001005238, respectively. The LC-MS/MS data have been deposited to the *PRoteomics* IDEntifications (*PRIDE*, <https://www.ebi.ac.uk/pride>) database under the accession number PRIDE: PXD014980.
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![Outline of the Study\
(A) Flow diagram of the study for tissue procurement in patients with advanced high-grade serous ovarian cancer (HGSC). PIV, predictive index value; TRS, tumor reduction surgery; NACT, neoadjuvant chemotherapy; R0, no residual disease; NACT-ER, excellent response to NACT; NACT-PR, poor response to NACT.\
(B) The areas of collection of tumor tissues from primary and multiple metastatic sites in patients with HGSC.\
(C) Multi-omics and downstream analyses were performed using DNA, RNA, proteins, and immune cells from tumor tissues. WGS, whole-genome sequencing; T200, high-depth targeted exome sequencing platform; LC-MS/MS, liquid chromatography-tandem mass spectrometry; RPPA, reverse phase protein array.](nihms-1584940-f0002){#F1}

![Somatic Mutations and CNVs Identified in Ovarian Cancer Genes\
(A) Oncoplots show the frequency of each type of somatic mutation in ovarian cancer genes for primary and metastatic samples. Each column represents one sample.\
(B) The frequency of CNVs identified in each ovarian-cancer-related gene. Each column represents one sample. Red represents copy gains, and black represents copy losses.\
(C) The enriched abnormalities, including somatic mutations and CNVs, in the R0 versus NACT-ER/PR groups with a significant p value of \< 0.05 in the group-wise comparison. The y axis represents the proportion of patient samples carrying the mutation in the corresponding genes.](nihms-1584940-f0003){#F2}

![CTLPs and Strong-Binding Neoantigens by Patient Group\
(A) CTLPs identified in nine different chromosomes in different patient groups.\
(B) The scatterplot of copy number status changes and the likelihood of CTLP in different patient groups.\
(C) Left: the number of strong-binding antigens detected in all tumors, including both primary and metastasis samples. Significant differences were observed between the R0 and NACT-ER/PR groups and between the R0 and NACT-PR groups. Middle: the number of strong-binding antigens detected in primary tumors. Significant differences were observed between the R0 and NACT-ER/PR groups and between the R0 and NACT-PR groups. Right: the number of strong-binding antigens detected in distant metastasis tumors. A peptide was identified as a strong binder if the % rank was below 0.5% or binding affinity (IC~50~) was below 50.](nihms-1584940-f0004){#F3}

![DEGs for the Groups, Identified by RNA-Seq, Proteomics, and Phosphoproteomics\
(A) Heatmap of 67 DEGs in the R0 compared to NACT-ER and NACT-PR groups.\
(B) Differential analyses of 7387 total proteins quantified and revealed 101 proteins significantly altered (adj. p \< 0.05) among NACT-ER (n = 30), NACT-PR (n = 29), and R0 (n = 28) patients. Heatmap reflects clusters assembled by Euclidean distance and average linkage of significant protein abundance trends.\
(C) Differential analyses of 12,914 total phosphosites quantified and revealed 71 phosphosites significantly altered (adj. p \< 0.05) among NACT-ER (n = 17), NACT-PR (n = 22), and R0 (n = 27) patients. Heatmap reflects clusters assembled by Pearson correlation and average linkage of significant phosphosite abundance trends.\
(D) Principle component analyses (PCAs) of 101 proteins significantly altered (adj. p \< 0.05) among NACT-ER (n = 30), NACT-PR (n = 29), and R0 (n = 28) patients.\
(E) PCA of 71 phosphosites significantly altered (adj. p \< 0.05) among NACT-ER (n = 17), NACT-PR (n = 22), and R0 (n = 27) patients.\
(F) *NF1* RNA expression pattern was consistent with the WGS findings. The boxplot shows the log2 normalized counts of *NF1* RNA in the R0, NACT-ER, and NACT-PR groups. The p values were calculated by differential analysis using DESeq2.\
(G) NF1 protein abundance was significantly elevated in NACT-ER and NACT-PR tumors versus R0 tumors. The boxplot reflects log2-fold change (L2FC) abundance of NF1 protein for the NACT-ER (n = 30), NACT-PR (n = 29), and R0 (n = 28) groups.\
(H) H-scores of NF1 expression by IHC for the NACT-ER (n = 12), NACT-PR (n = 14), and R0 (n = 24) groups. Statistical significance was determined by unpaired t test. Data are presented as the mean ± SEM.](nihms-1584940-f0005){#F4}

![HGSC Immune Infiltration Patterns\
(A) Relative distribution of analyzed cell phenotypes in the tumor area across the R0, NACT-ER, and NACT-PR groups.\
(B) Relative distribution of immune cell populations separated into primary and metastatic tumor sites in each group.\
(C) Immune subpopulation infiltration patterns in the R0, NACT-ER, and NACT-PR groups. The percentages of immune cells were compared for all T cells, immune cells, helper T cells, cytotoxic T cells, regulatory T cells, macrophages, and B cells. Statistical significance was determined by unpaired t test. Data are presented as the mean ± SEM.\
(D) Immune subpopulation infiltration patterns in primary and metastatic sites in tumor area only. The percentages of T cells, B cells, macrophages, and FoxP3^+^ cells in the tumor area were compared for each group.](nihms-1584940-f0006){#F5}

![Deconvolution Analysis of Cell Fractions Using RNA-Seq Data and the Concordance of Differentially Expressed Transcripts and Proteins among Groups\
(A) The composition of 22 immune cell subsets in each patient sample. The profiling of immune cells was inferred by deconvolution analysis of RNA-seq with the LM22 immune cell gene signature, and the relative percentages of different cell types are shown in the stacked bar plot.\
(B) Boxplots comparing the cell abundances of M2 macrophages and monocytes in the R0 and NACT-ER/PR groups based on RNA-seq deconvolution analysis. Consistent with the immune infiltrate analysis, the R0 group showed more abundant macrophages than did the NACT group.\
(C) Boxplot comparing the cell abundances of CD4^+^ T cells in primary and metastatic sites.\
(D) The 206 available transcript alterations were compared to proteins quantified and altered between NACT-ER (n = 30)/PR (n = 29) and R0 (n = 28) patients. Bar plot reflects the L2FC protein and transcript abundance trends for 10 co-measured candidates. \*Co-significantly altered at the protein and transcript levels in NACT-ER/PR (p \< 0.01) versus R0 groups.\
(E) The 263 available transcript alterations were compared to proteins quantified and altered between NACT-ER (n = 29) and NACT-PR (n = 30) patients. Bar plot reflects the L2FC protein and transcript abundance trends for the *KRT9* gene. \*Co-significantly altered protein (p \< 0.01) between NACT-ER and NACT-PR patients.](nihms-1584940-f0007){#F6}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                             SOURCE                                    IDENTIFIER
  --------------------------------------------------------------- ----------------------------------------- ------------------------------------------------------------------------
  Antibodies                                                                                                
  Anti-Neurofibromin-1 (NF1)                                      Abcam                                     Cat\# 128054, RRID:AB_11141828
  Biological Samples                                                                                        
  Patients with HGSC (tissues and blood)                          MDACC                                     N/A
  Chemicals, Peptides, and Recombinant Proteins                                                             
  Leica Bond Polymer Refine Detection kit                         Leica Biosystems                          Cat\#DS9800
  Quant-iT PicoGreen dsDNA reagent                                Invitrogen                                Cat\# P7581
  SMART trypsin                                                   Thermo Fisher Scientific                  Cat\# 60109
  TMT-11-plex Isobaric Label Reagent Set                          Thermo Fisher Scientific                  Cat\# A34807
  Acclaim™ PepMap™ 100 C18                                        Thermo Fisher Scientific                  Cat\# 164567
  Acclaim™ PepMap™ RSLC C18                                       Thermo Fisher Scientific                  Cat\# 164540
  Critical Commercial Assays                                                                                
  QIAamp DNA Mini Kit                                             QIAGEN                                    Cat\# 51304
  QIAamp DNA Blood Mini Kit                                       QIAGEN                                    Cat\# 51104
  TruSeq DNA PCR-Free Library Prep Kit                            Illumina                                  Cat\# 20015963
  High Sensitivity dsDNA Kit                                      Advanced Analytical Technologies, Inc.    Cat\# DNF-468--0500
  KAPA SYBR FAST Library Quantification Kit                       KAPA Biosystems                           Cat\# KK4824
  HiSeq X HD Paired-End Cluster Generation Kit v2                 Illumina                                  Cat\# GD-410--1001
  HiSeq X HD SBS Kit (300 cycles)                                 Illumina                                  Cat\# FC-410--1003
  Agencourt AMPure PCR purification kit                           Agencourt Bioscience Corporation          Cat\# A63880
  KAPA qPCR Quantification Kit                                    KAPA Biosystems                           Cat\# KK4600
  whole-exome biotin-labeled probes (v3)                          Roche NimbleGen                           Cat\# 06465684001
  Ovation RNA-Seq System V2 kit                                   NuGEN                                     Cat\# 7102
  Pierce BCA Protein Assay Kit                                    Thermo Fisher Scientific                  Cat\# 23225
  High-Select TiO~2~ Phosphopeptide Enrichment Kit                Thermo Fisher Scientific                  Cat\# A32992
  Deposited Data                                                                                            
  WGS data                                                        This paper                                EGA: EGAD00001005240
  Deep targeted sequencing data                                   This paper                                EGA: EGAD00001005239
  RNA sequencing data                                             This paper                                EGA: EGAD00001005238
  LC-MS/MS data                                                   This paper                                PRIDE: PXD014980
  Software and Algorithms                                                                                   
  BWA software package                                            [@R43]                                    N/A
  Picard tools                                                    Broad Institute                           <http://broadinstitute.github.io/picard/>
  GATK toolkit                                                    [@R54]                                    N/A
  MuTect method                                                   [@R11]                                    N/A
  Sequenza package                                                [@R20]                                    N/A
  PyClone model                                                   [@R70]                                    N/A
  PHYLIP program                                                  [@R68]                                    N/A
  HMMcopy                                                         Haetal., 2012                             N/A
  Circular binary segmentation                                    [@R62]                                    N/A
  CNsignatures algorithm                                          [@R51]                                    N/A
  LUMPY                                                           [@R40]                                    N/A
  BRASS                                                           Cancer IT                                 <https://github.com/cancerit/BRASS>
  BreakDancer                                                     [@R19]                                    N/A
  CTLPScanner server                                              [@R90]                                    N/A
  COSMIC database                                                 [@R4]                                     N/A
  TelSeq software                                                 [@R14]                                    N/A
  NetMHCcons server                                               [@R32]                                    N/A
  Spliced Transcripts Alignment to a Reference (STAR) algorithm   [@R15]                                    N/A
  FastQC and Qualimap tool                                        [@R60]                                    N/A
  Web-based gene set analysis toolkit (WebGestalt)                [@R83]; [@R92]                            N/A
  KEGG                                                            Kyoto Encyclopedia of Genes and Genomes   <https://www.kegg.jp/>
  Reactome                                                        Reactome                                  <https://reactome.org>
  PANTHER                                                         Panther Geneontology                      <http://www.pantherdb.org/>
  MicroVigene software                                            VigeneTech                                N/A
  R package Super-Curve (version 1.01)                            MDACC                                     <https://bioinformatics.mdanderson.org/public-software/archive/oompa/>
  GeneMANIA server                                                [@R85]                                    N/A
  Non-redundant human proteome database                           Swiss-Prot                                <https://www.uniprot.org/>
  Proteome Discoverer                                             Thermo Fisher Scientific                  N/A
  Mascot                                                          Matrix Science                            N/A
  PAMR (Prediction Analysis for Microarrays) R package            [@R41]                                    N/A
  Mann-Whitney U rank sum testing                                 MedCalc (version 19.0.3).                 
  LIMMA package (version 3.8)                                     [@R69]                                    N/A
  ClustVis web tool                                               [@R56]                                    N/A
  BWA and Picard                                                  [@R13]                                    N/A
  In-house R package                                              [@R78]                                    N/A
  CIBERSORTtool                                                   Stanford University                       <https://cibersort.stanford.edu>
  DESeq2                                                          [@R50]                                    N/A
  GraphPad Prism                                                  GraphPad Software                         N/A

###### Highlights

-   High rate of NF1 loss in the R0 compared to neoadjuvant chemotherapy (NACT) group

-   Lower chromothripsis-like pattern and higher neoantigens in the R0 versus NACT group

-   Increased number of infiltrated T cells and decreased macrophages in the R0 group

-   Significant transcriptomic and proteomic variations between HGSC subgroups
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